Loading...

News List

HR+乳腺癌创新疗法!阿斯利康下一代雌激素受体降解剂camizestrant 3期临床疗效显著!

2022-10-28


HR+乳腺癌创新疗法!阿斯利康下一代雌激素受体降解剂camizestrant 3期临床疗效显著!

 阿斯利康(AstraZeneca)近日公布了SERENA-2 II期试验的阳性高水平结果。这是一项随机、开放标签、平行组、多中心2期试验,是一个大规模临床项目的一部分,该项目专注于研究camizestrant,这是一种强效的下一代口服选择性雌激素受体降解剂和纯粹的雌激素受体α拮抗剂,正被开发作为单药疗法或与其他药物联合使用,以解决激素受体阳性乳腺癌领域存在的未满足医疗需求。

Pre: Huatangning, the world's first new hypoglycemic drug was approved

Next: HR+ Innovative treatment for Breast cancer! Astrazeneca's next generation estrogen receptor depressant camizestrant phase 3 clinical efficacy is remarkable!

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.